CA2521812A1 - Optimal polyvalent vaccine for cancer - Google Patents

Optimal polyvalent vaccine for cancer Download PDF

Info

Publication number
CA2521812A1
CA2521812A1 CA002521812A CA2521812A CA2521812A1 CA 2521812 A1 CA2521812 A1 CA 2521812A1 CA 002521812 A CA002521812 A CA 002521812A CA 2521812 A CA2521812 A CA 2521812A CA 2521812 A1 CA2521812 A1 CA 2521812A1
Authority
CA
Canada
Prior art keywords
antigens
cancer
vaccine
cell
polyvalent vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002521812A
Other languages
English (en)
French (fr)
Inventor
Philip O. Livingston
Govindaswami Ragupathi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sloan Kettering Institute for Cancer Research
Original Assignee
Sloan-Kettering Institute For Cancer Research
Philip O. Livingston
Govindaswami Ragupathi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan-Kettering Institute For Cancer Research, Philip O. Livingston, Govindaswami Ragupathi filed Critical Sloan-Kettering Institute For Cancer Research
Publication of CA2521812A1 publication Critical patent/CA2521812A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
CA002521812A 2003-04-09 2004-04-09 Optimal polyvalent vaccine for cancer Abandoned CA2521812A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46162203P 2003-04-09 2003-04-09
US60/461,622 2003-04-09
PCT/US2004/011122 WO2004091507A2 (en) 2003-04-09 2004-04-09 Optimal polyvalent vaccine for cancer

Publications (1)

Publication Number Publication Date
CA2521812A1 true CA2521812A1 (en) 2004-10-28

Family

ID=33299843

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002521812A Abandoned CA2521812A1 (en) 2003-04-09 2004-04-09 Optimal polyvalent vaccine for cancer

Country Status (4)

Country Link
EP (1) EP1615614A4 (ja)
JP (1) JP2006522828A (ja)
CA (1) CA2521812A1 (ja)
WO (1) WO2004091507A2 (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002354804A1 (en) 2001-07-06 2003-01-21 Sloan-Kettering Institute For Cancer Research Polyvalent conjugate vaccine for cancer
US20060035267A1 (en) * 2003-04-09 2006-02-16 Livingston Philip O Optimal polyvalent vaccine for cancer
CN101356195B (zh) 2005-12-08 2013-04-03 米德列斯公司 抗岩藻糖基-gm1的人单克隆抗体及使用抗岩藻糖基-gm1抗体的方法
US9125848B2 (en) 2010-06-10 2015-09-08 The Cleveland Clinic Foundation Alpha lactalbumin immunization methods
EP2839291B1 (en) 2012-04-16 2018-07-04 The Cleveland Clinic Foundation Multivalent breast cancer vaccine
JP2015227292A (ja) * 2014-05-30 2015-12-17 国立大学法人高知大学 膵がん細胞浸潤転移抑制ワクチン
JP2019525138A (ja) * 2016-06-16 2019-09-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｄｃを誘発する抗体を決定するためのアッセイ法および方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002354804A1 (en) * 2001-07-06 2003-01-21 Sloan-Kettering Institute For Cancer Research Polyvalent conjugate vaccine for cancer

Also Published As

Publication number Publication date
EP1615614A2 (en) 2006-01-18
EP1615614A4 (en) 2007-08-22
WO2004091507A2 (en) 2004-10-28
JP2006522828A (ja) 2006-10-05
WO2004091507A3 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
US20060035267A1 (en) Optimal polyvalent vaccine for cancer
Ragupathi et al. Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity
Livingston et al. Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy
Zappasodi et al. Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death
US10792349B2 (en) Galectin-3 as immunological target
Sabbatini et al. Immunization of ovarian cancer patients with a synthetic Lewisy‐protein conjugate vaccine: A phase 1 trial
Krug et al. Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin
Ragupathi et al. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3‐lactone‐KLH conjugate plus immunological adjuvant QS‐21
Dickler et al. Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer
Ragupathi et al. A fully synthetic globo H carbohydrate vaccine induces a focused humoral response in prostate cancer patients: a proof of principle
Reed et al. Vaccination with melanoma helper peptides induces antibody responses associated with improved overall survival
Gregor et al. Induction of autoantibodies to syngeneic prostate‐specific membrane antigen by xenogeneic vaccination
JP5876411B2 (ja) ポルフィロモナス・ジンジバリス（Ｐｏｒｐｈｙｒｏｍｏｎａｓｇｉｎｇｉｖａｌｉｓ）ポリペプチド
Kawada et al. Heteroclitic serological response in esophageal and prostate cancer patients after NY‐ESO‐1 protein vaccination
Dettling et al. Identification of CRKII, CFL1, CNTN1, NME2, and TKT as novel and frequent T-cell targets in human IDH-mutant glioma
Trabbic et al. Immunological evaluation of the entirely carbohydrate-based Thomsen-Friedenreich–PS B conjugate
CA2521812A1 (en) Optimal polyvalent vaccine for cancer
US20120064102A1 (en) Peptide inducing xage-1b-specific immune reaction and utilization of same
Zhang et al. Increased tumor cell reactivity and complement-dependent cytotoxicity with mixtures of monoclonal antibodies against different gangliosides
Manjili et al. Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce “danger signals”
US20070116704A1 (en) Method for the production of an immunostimulating mucin (muc1)
US20080241195A1 (en) Optimal Polyvalent Vaccine for Cancer
Ritter et al. Induction of antibodies reactive with GM2 ganglioside after immunization with lipopolysaccharides from Campylobacter jejuni
Cappello et al. Immunization of mice with fucosyl-GM1 conjugated with keyhole limpet hemocyanin results in antibodies against human small-cell lung cancer cells
US20090074773A1 (en) Cancer vaccine

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead